Reithera Srl is a contract development and manufacturing organization devoted to developing and producing biopharmaceutical products based on gene delivery technologies for advanced therapies, which can prevent and treat several severe or life-threatening diseases.
The company has expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAVx), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Anka...kara and Herpes Simplex Vector.
The core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, and fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.
Reithera headquarters, R&D laboratories, and GMP facilities are in Rome, Italy.
